Saredutant

Saredutant
Systematic (IUPAC) name
	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
Identifiers
CAS Number	142001-63-6
ATC code	none
PubChem	CID: 104974
IUPHAR/BPS	2111
ChemSpider	94726
ChEMBL	CHEMBL308148
Chemical data
Formula	C31H35Cl2N3O2
Molecular mass	552.5345 g/mol
	SMILES Clc1ccc(cc1Cl)[C@H](CCN3CCC(c2ccccc2)(NC(=O)C)CC3)CN(C(=O)c4ccccc4)C ;
	InChI InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1 ; Key:PGKXDIMONUAMFR-AREMUKBSSA-N ;
(what is this?) (verify)

Saredutant (SR-48,968) is a drug that acts as a NK₂ receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.^[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.